{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:02:17Z","timestamp":1787313737675,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.pbb.2020.173073","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T01:22:22Z","timestamp":1605057742000},"page":"173073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder"],"prefix":"10.1016","volume":"200","author":[{"given":"Sana","family":"Tafseer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2020.173073_bb0005","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.mehy.2003.11.044","article-title":"Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis","volume":"64","author":"Altschuler","year":"2005","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.pbb.2020.173073_bb0010","author":"American Psychiatric, A"},{"key":"10.1016\/j.pbb.2020.173073_bb0015","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0149-2918(00)83028-3","article-title":"Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis","volume":"22","author":"Beasley","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pbb.2020.173073_bb0020","first-page":"466","article-title":"Psychotropics and sexual dysfunction","volume":"66","author":"Bella","year":"2014","journal-title":"Central European journal of urology"},{"key":"10.1016\/j.pbb.2020.173073_bb0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/157015908785777238","article-title":"The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology","volume":"6","author":"Berthold-Losleben","year":"2008","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0030","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1017\/S1461145708009309","article-title":"A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression","volume":"11","author":"Brunoni","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0035","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00213-013-3322-3","article-title":"Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial","volume":"231","author":"Brunoni","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2020.173073_bb0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1345\/aph.1A254","article-title":"Discontinuing or switching selective serotonin-reuptake inhibitors","volume":"36","author":"Bull","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pbb.2020.173073_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41398-019-0521-7","article-title":"Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies","volume":"9","author":"Carboni","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.pbb.2020.173073_bb0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/npp.2012.191","article-title":"Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline \u201cpredictors\u201d and longitudinal \u201ctargets.\u201d","volume":"38","author":"Cattaneo","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2020.173073_bb0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.psyneuen.2017.10.009","article-title":"Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder","volume":"87","author":"Chen","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2020.173073_bb0065","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4088\/JCP.v67n0507","article-title":"Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies","volume":"67","author":"Clayton","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0070","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0149-2918(01)80090-4","article-title":"A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine","volume":"23","author":"Coleman","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pbb.2020.173073_bb0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0149-2918(00)88317-4","article-title":"A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline","volume":"21","author":"Croft","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pbb.2020.173073_bb0080","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0149-2918(02)85141-4","article-title":"Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks","volume":"24","author":"Croft","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pbb.2020.173073_bb0085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/00023210-200822070-00006","article-title":"Spotlight on bupropion in major depressive disorder","volume":"22","author":"Dhillon","year":"2008","journal-title":"CNS drugs"},{"key":"10.1016\/j.pbb.2020.173073_bb0090","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.pnpbp.2007.09.015","article-title":"Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder","volume":"32","author":"Eller","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0095","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/0269881108091077","article-title":"Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder","volume":"23","author":"Eller","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0100","first-page":"106","article-title":"15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL","volume":"7","author":"Fava","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0105","first-page":"329","article-title":"Double-blind comparison of bupropion and fluoxetine in depressed outpatients","volume":"52","author":"Feighner","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0110","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/14737175.6.9.1249","article-title":"Bupropion: pharmacology and therapeutic applications","volume":"6","author":"Foley","year":"2006","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.pbb.2020.173073_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajp.2015.10.006","article-title":"Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine","volume":"18","author":"Ghosh","year":"2015","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.pbb.2020.173073_bb0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00406-005-0578-6","article-title":"Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients","volume":"255","author":"Gonul","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pbb.2020.173073_bb0125","first-page":"108","article-title":"Safety and efficacy of bupropion extended release in treating a community sample of Hispanic and african american adults with major depressive disorder: an open-label study","volume":"9","author":"Gross","year":"2007","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000444220","article-title":"Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-alpha in patients of major depressive disorder with severe depression","volume":"97","author":"Gupta","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.pbb.2020.173073_bb0135","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/jcph.963","article-title":"Effect of agomelatine and fluoxetine on HAM-D score, serum brain-derived Neurotrophic factor, and tumor necrosis factor-\u03b1 level in patients with major depressive disorder with severe depression","volume":"57","author":"Gupta","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.psyneuen.2018.05.026","article-title":"Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder","volume":"95","author":"Haroon","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2020.173073_bb0150","first-page":"183","article-title":"Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy","volume":"19","author":"Hestad","year":"2003","journal-title":"PloS one The journal of ECT"},{"key":"10.1016\/j.pbb.2020.173073_bb0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0269881108089602","article-title":"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","volume":"23","author":"Hewett","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eurpsy.2008.03.013","article-title":"Depression, comorbidities and the TNF-alpha system","volume":"23","author":"Himmerich","year":"2008","journal-title":"European psychiatry\u202f: the journal of the Association of European Psychiatrists"},{"key":"10.1016\/j.pbb.2020.173073_bb0165","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4088\/JCP.v65n0712","article-title":"Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate","volume":"65","author":"Hu","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jpsychires.2007.05.007","article-title":"Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants","volume":"42","author":"Huang","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pbb.2020.173073_bb0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jad.2018.04.037","article-title":"Elevated tumor necrosis factor-alpha receptor subtype 1 and the association with abnormal brain function in treatment-resistant depression","volume":"235","author":"Huang","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pbb.2020.173073_bb0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0168-8278(03)00172-7","article-title":"Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion","volume":"39","author":"Kast","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.pbb.2020.173073_bb0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S109285291200051X","article-title":"Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)","volume":"17","author":"Katsuki","year":"2012","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pbb.2020.173073_bb0190","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4088\/JCP.v58n1204","article-title":"Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients","volume":"58","author":"Kavoussi","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0195","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.pnpbp.2007.03.004","article-title":"Cytokine imbalance in the pathophysiology of major depressive disorder","volume":"31","author":"Kim","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/acps.12698","article-title":"Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies","volume":"135","author":"K\u00f6hler","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pbb.2020.173073_bb0205","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0162-3109(95)00026-P","article-title":"The effect of chronic treatment with imipramine on the immunoreactivity of animals subjected to a chronic mild stress model of depression","volume":"30","author":"Kubera","year":"1995","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.pbb.2020.173073_bb0210","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0893-133X(99)00134-7","article-title":"Cytokine production and treatment response in major depressive disorder","volume":"22","author":"Lanquillon","year":"2000","journal-title":"Neuropsychopharmacology\u202f: official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2020.173073_bb0215","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000149817","article-title":"Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants","volume":"57","author":"Lee","year":"2008","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pbb.2020.173073_bb0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4306\/pi.2010.7.4.231","article-title":"The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment","volume":"7","author":"Lee","year":"2010","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.pbb.2020.173073_bb9000","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.pra.0000336754.19566.65","article-title":"An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder","volume":"14","author":"Leuchter","year":"2008","journal-title":"Journal of psychiatric practice"},{"key":"10.1016\/j.pbb.2020.173073_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00052","article-title":"Exercise-mediated neurogenesis in the Hippocampus via BDNF","volume":"12","author":"Liu","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2020.173073_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050733","article-title":"Pathogenetic and therapeutic applications of tumor necrosis factor-alpha (TNF-alpha) in major depressive disorder: a systematic review","volume":"17","author":"Ma","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2020.173073_bb0235","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3","article-title":"A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies","volume":"6","author":"Mackay","year":"1997","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.pbb.2020.173073_bb0240","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.physbeh.2017.11.009","article-title":"Distinct inflammatory response patterns are evident among men and women with higher depressive symptoms","volume":"184","author":"Majd","year":"2018","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2020.173073_bb0245","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1523\/JNEUROSCI.20-24-09104.2000","article-title":"Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus","volume":"20","author":"Malberg","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2020.173073_bb0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharep.2013.06.003","article-title":"The influence of mianserin on TNF-alpha, IL-6 and IL-10 serum levels in rats under chronic mild stress","volume":"66","author":"Manikowska","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pbb.2020.173073_bb0255","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4088\/JCP.08l04477","article-title":"Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study","volume":"70","author":"Maron","year":"2009","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157015912800604542","article-title":"Immunomodulation mechanism of antidepressants: interactions between serotonin\/norepinephrine balance and Th1\/Th2 balance","volume":"10","author":"Martino","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0265","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.pbb.2020.173073_bb0270","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mp.2013.105","article-title":"Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484)","volume":"19","author":"Molendijk","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0275","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbr.2013.12.038","article-title":"Depressive-like behavior induced by tumor necrosis factor-alpha is abolished by agmatine administration","volume":"261","author":"Neis","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2020.173073_bb0280","first-page":"106","article-title":"Duloxetine for the treatment of major depressive disorder","volume":"36","author":"Nemeroff","year":"2002","journal-title":"Psychopharmacol. Bull."},{"issue":"Suppl. 16","key":"10.1016\/j.pbb.2020.173073_bb0285","first-page":"5","article-title":"Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression","volume":"62","author":"Nierenberg","year":"2001","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0290","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1345\/aph.1A099","article-title":"Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression","volume":"35","author":"Nieuwstraten","year":"2001","journal-title":"Ann. Pharmacother."},{"issue":"Suppl. 6","key":"10.1016\/j.pbb.2020.173073_bb0295","first-page":"3","article-title":"The role of dopamine and norepinephrine in depression and antidepressant treatment","volume":"67","author":"Nutt","year":"2006","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0300","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jpsychires.2006.05.013","article-title":"Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy","volume":"41","author":"O\u2019Brien","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pbb.2020.173073_bb0305","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.4103\/1673-5374.235219","article-title":"Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson\u2019s disease","volume":"13","author":"O\u2019Neill","year":"2018","journal-title":"Neural Regen. Res."},{"issue":"Suppl E1","key":"10.1016\/j.pbb.2020.173073_bb0310","first-page":"8","article-title":"Tolerability of modern antidepressants","volume":"69","author":"Papakostas","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/2045125316629071","article-title":"Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant","volume":"6","author":"Patel","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.pbb.2020.173073_bb0320","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1741-7015-11-129","article-title":"Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile","volume":"11","author":"Penninx","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.pbb.2020.173073_bb0325","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.euroneuro.2012.09.009","article-title":"Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response","volume":"23","author":"Powell","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0330","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/j.1460-9568.2006.05059.x","article-title":"Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment","volume":"24","author":"Rossi","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2020.173073_bb0335","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/0269881111431748","article-title":"The hidden third: improving outcome in treatment-resistant depression","volume":"26","author":"Schlaepfer","year":"2012","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.pbb.2020.173073_bb0340","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.4103\/1673-5374.235019","article-title":"Molecular mechanism of noradrenaline during the stress-induced major depressive disorder","volume":"13","author":"Seki","year":"2018","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.pbb.2020.173073_bb0345","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.biopsych.2008.05.005","article-title":"Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications","volume":"64","author":"Sen","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0350","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0033-1353171","article-title":"An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features","volume":"46","author":"Seo","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0355","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1192\/bjp.180.5.396","article-title":"Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis","volume":"180","author":"Smith","year":"2002","journal-title":"The British journal of psychiatry : the journal of mental science"},{"key":"10.1016\/j.pbb.2020.173073_bb0360","first-page":"159","article-title":"A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor","volume":"6","author":"Stahl","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0365","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","article-title":"Inflammation and clinical response to treatment in depression: a meta-analysis","volume":"25","author":"Strawbridge","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0370","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jad.2018.12.037","article-title":"Inflammatory profiles of severe treatment-resistant depression","volume":"246","author":"Strawbridge","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pbb.2020.173073_bb0375","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4088\/JCP.v66n0803","article-title":"Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials","volume":"66","author":"Thase","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0380","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2008.02.013","article-title":"Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels","volume":"134","author":"Tousoulis","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.pbb.2020.173073_bb0385","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.pnpbp.2006.01.029","article-title":"Cytokines and serotonin transporter in patients with major depression","volume":"30","author":"Tsao","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0390","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00213-003-1566-z","article-title":"Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder","volume":"170","author":"Tuglu","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2020.173073_bb0395","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5498\/wjp.v5.i3.330","article-title":"Pharmacologic approaches to treatment resistant depression: evidences and personal experience","volume":"5","author":"Tundo","year":"2015","journal-title":"World J Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb8000","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0033291711001905","article-title":"Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms","volume":"42","author":"Uher","year":"2012","journal-title":"Psychological medicine"},{"key":"10.1016\/j.pbb.2020.173073_bb0400","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1038\/tp.2012.8","article-title":"Association of depressive disorders, depression characteristics and antidepressant medication with inflammation","volume":"2","author":"Vogelzangs","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jad.2012.06.007","article-title":"Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis","volume":"144","author":"von Wolff","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pbb.2020.173073_bb0410","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181dbfd04","article-title":"Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report","volume":"30","author":"Warden","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2020.173073_bb0415","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4088\/JCP.v61n0309","article-title":"Bupropion sustained release versus paroxetine for the treatment of depression in the elderly","volume":"61","author":"Weihs","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0420","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.pnpbp.2009.03.020","article-title":"Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression","volume":"33","author":"Yoshimura","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2020.173073_bb0425","first-page":"982","article-title":"Blood levels of brain-derived neurotrophic factor (BDNF) in major depressive disorder","volume":"112","author":"Yoshimura","year":"2010","journal-title":"Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica"},{"key":"10.1016\/j.pbb.2020.173073_bb0430","first-page":"e0197267","article-title":"Changes in the serum levels of inflammatory cytokines in antidepressant drug-naive patients with major depression","volume":"13","author":"Zou","year":"2018"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305718306191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305718306191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:39:01Z","timestamp":1758775141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305718306191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":88,"alternative-id":["S0091305718306191"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2020.173073","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2020.173073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173073"}}